Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sysmex Develops in Vitro Diagnostic Technology for Cancers
January 29, 2007
- REGULATORY NEWS IN BRIEF
January 29, 2007
- Korosho Proposes "Medical Device MR System"
January 29, 2007
- Development of Amlodipine + Atorvastatin Combination Underway in Japan: Pfizer
January 29, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 29, 2007
- Ankhs Develops Drugs for Metastatic Cancer Using NR Ligands
January 29, 2007
- Retirement of Baby Boomers to Change Structure of Social Security System: Mr Kawasaki
January 29, 2007
- Kissei Announces Positive Results from PIII Trials of Silodosin in the US
January 29, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 29, 2007
- Enrollment Completed for PIII of Prasugrel: Daiichi Sankyo
January 29, 2007
- TOPIC an article
January 29, 2007
- Molecular Imaging Research Symposium 2007
January 29, 2007
- Generic Companies, Med. Device Makers to Become Targets of M&A: Mr Yamaguchi of Nikko Citigroup
January 29, 2007
- Japan Should Participate in More Multinational Trials: Dr Sato of PMDA
January 29, 2007
- MPC, Tanabe Discuss Merger -Merger to Give Birth to 6th Largest Japanese Company-
January 29, 2007
- Study Group for Early Approval of Drugs to Focus on Microdosing Studies
January 29, 2007
- 58.2% Aware of DTC Disease Education Ads
January 29, 2007
- R&DNEWS IN BRIEF
January 29, 2007
- Globalization Essential to Growth of Domestic Bioventures: Mr Yamazaki
January 29, 2007
- Novartis Begins Independent Sale of OTC Drugs
January 29, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…